A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data
| Autor: | Parneet Cheema, Byoung Chul Cho, Helano Freitas, Mariano Provencio, Yuh Min Chen, Sang-We Kim, Yi-Long Wu, Antonio Passaro, Claudio Martin, Marcello Tiseo, Gee-Chen Chang, Keunchil Park, Benjamin Solomon, Otto Burghuber, Janessa Laskin, Ziping Wang, Sung Yong Lee, Yanping Hu, Johan Vansteenkiste, He-long Zhang, Emer Hanrahan, Thomas Geldart, Rosemary Taylor, Leslie Servidio, Jingyi Li, Filippo de Marinis |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Future Oncology. 19:61-75 |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | Aim: Report the final analysis from ASTRIS, the largest real-world study of second-/later-line osimertinib in advanced/metastatic EGFR T790M non-small-cell lung cancer (NSCLC). Methods: Patients with advanced/metastatic EGFR T790M NSCLC and prior EGFR-TKI treatment, received once-daily osimertinib 80 mg. Primary end point: overall survival (OS); secondary end points: progression-free survival (PFS), time-to-treatment discontinuation (TTD) and response rate. Safety was also recorded. Results: In 3014 patients, median OS: 22.8 months (21.6–23.8), median PFS: 11.1 months (11.0–12.0), median TTD: 13.5 months (12.6–13.9), and response rate: 57.3% (55.5–59.2). All end points reported with 95% CIs. Numerically longer median OS was observed in patients with baseline WHO performance status Clinical Trial Registration: NCT02474355 ( ClinicalTrials.gov ) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|